abstract |
The present invention provides a method of treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody alone or in combination with an anti-CTLA4 antibody in a patient identified using a polynucleotide marker (e.g., IFNy) of the present invention. |